About
Small Molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Team (14)
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
8
As Collaborator
0
Total Enrollment
381
By Phase
PHASE2: 3PHASE3: 4PHASE2/PHASE3: 1
By Status
COMPLETED: 5RECRUITING: 3
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06653842Lead Sponsor
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
PHASE2Recruiting
15 participants
Started: Dec 20, 2024 · Completed: Mar 31, 2026
NCT06239480Lead Sponsor
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
PHASE3Recruiting
40 participants
Started: Jul 31, 2024 · Completed: Jul 31, 2026
NCT05643872Lead Sponsor
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
PHASE3Recruiting
45 participants
Started: Nov 15, 2022 · Completed: Nov 30, 2023
NCT05050149Lead Sponsor
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
PHASE2Completed
12 participants
Started: Jan 13, 2022 · Completed: Dec 15, 2022
NCT05180708Lead Sponsor
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
PHASE3Completed
87 participants
Started: Nov 29, 2021 · Completed: Jun 30, 2023
Locations (1)
Headquarters
Wayne, PA, United States
Map
Loading map...